Seroprevalence of Hepatitis a in Hemodialysis Patient Candidate for Kidney Transplant Younger Than Forty Years
Novelty in Biomedicine,
Vol. 5 No. 2 (2017),
24 April 2017
,
Page 49-53
https://doi.org/10.22037/nbm.v5i2.11979
Abstract
Background: Hepatitis A is a common infection during childhood, especially in developing countries. It can cause severe complications in immunocompromised patients. Due to the increasing number of kidney transplants in the country and epidemiologic shift of HAV which was observed in previous studies, we're going to evaluate the seroprevalence of hepatitis A in hemodialysis patients less than forty years serving kidney transplant candidates to follow vaccination policy for them.Materials and Methods: In a cross sectional study during 2014-2015 hepatitis A antibody levels in hemodialysis patients less than forty years in kidney transplant candidates examined in 12 hospitals in Tehran, Iran. Their serums were tested for anti HAV IgM and IgG by ELISA kits.
Results: Hepatitis A virus antibody was positive in 66 (72.5%) of 91 patients. The prevalence of HAV was 0% at the range of younger than 20 and 45% in under 25 years age group. This significantly increased prevalence by increasing the age, and there was according to epidemiological shifts which were shown in other studies.
Conclusion: Due to the availability of vaccine and hepatitis severe complications in immunocompromised individuals, as well as a low prevalence of positive serology in individuals under 25 years, it seems the check of antibodies in patients undergoing kidney transplantation and vaccination in seronegative persons is a logical.
- Dialysis
- Hepatitis A
- Seroprevalence
How to Cite
References
Jacobsen K, Koopman J. Declining hepatitis A seroprevalence: a global review and analysis. Epidemiology and infection. 2004;132:1005-1022.
Hendrickx G. Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology. Journal of viral hepatitis. 2008;15:1-15.
Melnick J L. History and epidemiology of hepatitis A virus. Journal of Infectious Diseases. 1995;171:S2-S8.
Jacobsen K, Koopman J. The effects of socioeconomic development on worldwide hepatitis A virus seroprevalence patterns. International Journal of Epidemiology. 2005;34:600-9.
Gust I D. Epidemiological patterns of hepatitis A in different parts of the world. Vaccine. 1992;10:S56-S58.
Franco E, Meleleo C, Serino L, Sorbara D, Zaratti L.
Farzadegan H, Shamszad M, Noori-Arya K. Epidemiology of viral hepatitis among Iranian population--a viral marker study. Annals of the Academy of Medicine, Singapore. 1980;9:144-8.
Pourshams A. Golestan cohort study of oesophageal cancer: feasibility and first results. British journal of cancer. 2005;92:176-81.
Wood A J, Lemon S M, Thomas D L. Vaccines to prevent viral hepatitis. New England journal of medicine. 1997;336:196-204.
Kuramoto I, Fujiyama S, Matsushita K, Sato T. Immune response after hepatitis A vaccination in haemodialysis patients: comparison with hepatitis B vaccination. Journal of gastroenterology and hepatology. 1994;9:228-31.
Hoofnagle J H, Doo E, Liang T J, Fleischer R, Lok A S. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007;45:1056-75.
Aoufi S. In Transplantation proceedings. 2946-2948 (Elsevier).
Mathur P, Arora N. Epidemiological transition of hepatitis A in India: issues for vaccination in developing countries. Indian Journal of Medical Research. 2008;128, 699.
Das K. The changing epidemiological pattern of hepatitis A in an urban population of India: emergence of a trend similar to the European countries. European journal of epidemiology. 2000;16:507-10.
Malekzadeh R, Khatibian M, Rezvan H. Viral hepatitis in the world and Iran. J Irn Med Council. 1997;15:183-200.
Ahmed M. High prevalence of hepatitis A virus antibody among Bangladeshi children and young adults warrants pre-immunization screening of antibody in HAV vaccination strategy. Indian journal of medical microbiology. 2009;27, 48.
Saha S. Seroprevalence of Hepatitis A Infection by Age Group and Socioeconomic Status in Bangladesh. International Journal of Infectious Diseases. 2008;12:101-2.
Farajzadegan Z. Systematic review and meta-analysis on the age-specific seroprevalence of hepatitis A in Iran. Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences. 2014;19:56.
Mahdavi-Mazdeh M. Renal replacement therapy in Iran. Urol J. 2007;4:66-70.
Duchini A. Goss J A. Karpen S, Pockros P J. Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. Clinical microbiology reviews. 2003;16:357-64.
Stark, K. et al, Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients. Journal of Infectious Diseases. 1999;180:2014-7.
Jeon H. Efficacy and safety of hepatitis A vaccination in kidney transplant recipients. Transplant Infectious Disease. 2014;16:511-5.
Darwish M A, Faris R, Clemens J D, Rao M R, Edelman R. High seroprevalence of hepatitis A, B, C, and E viruses in residents in an Egyptian village in The Nile Delta: a pilot study. The American journal of tropical medicine and hygiene. 1996;54:554-8.
Abdal Aziz A, Awad M. Seroprevalence of hepatitis A virus antibodies among a sample of Egyptian children; 2008.
Salama I, Samy S, Shaaban F, Hassanin A, Abou Ismail L. Seroprevalence of hepatitis A among children of different socioeconomic status in Cairo; 2007.
Gentile A. The need for an evidence‐based decision‐making process with regard to control of hepatitis A. Journal of viral hepatitis. 2008;15:16-21.
- Abstract Viewed: 687 times
- PDF Downloaded: 3652 times